Among the 294 patients (39.9%) for whom mutational analysis was available, patients affected by GISTs with mutations in KIT had a significantly higher risk of relapse (log-rank P = .03) compared with patients with molecular alterations involving PDGFRA (platelet-derived growth factor α) or other genes (eg, BRAF, SDH, [succinate dehydrogenase] NF-1 [(neurofibromatosis type 1]) (HR, 2.77; 95% CI, 1.05-7.27; P = .04). This evidence concerns the gene BRAF and neurofibromatosis.